Regulation of human dihydropyrimidime dehydrogenase: Implications in the pharmacogenetics of 5-FU-based chemotheraphy

Pharmacogenomics

Volumn 8, Issue 3, 2007, Pages 257-265

  Zhang, Xue ^a   Diasio, Robert B ^b  

^a University of Alabama at Birmingham   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Dihydropyrimidine dehydrogenase; Dihydropyrimidine dehydrogenase gene; Gene regulation; Promoter methylation

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLUOROURACIL; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; ANTINEOPLASTIC ANTIMETABOLITE;

CANCER CHEMOTHERAPY; CELL DENSITY; CELL GROWTH; CIRCADIAN RHYTHM; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; NEOPLASM; PHYSIOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 33947607213     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.3.257     Document Type: Review

References (79)

1. Johnston SJ, Ridge SA, Cassidy J, McLeod HL: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res. 5 (9), 2566-2570(1999).
2. Johnson MR, Diasio RB: Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Requl. 41, 151-157 (2001).
3. Yong WP Innocenti F, Ratain MJ: rMe role of pharmacogenetics in cancer therapeutics. Br. J Clin. Pharmacol. 62(1), 35-46 (2006).
4. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16(4), 215-237 (1989).
5. Dobritzsch D, Schneider G, Schnackerz KD, Lindqvist Y: Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 20(4), 650-660 (2001).
6. Mattison LK, Soong R, Diasio RB: Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacagenomics3(4), 485-492 (2002).
7. Diasio RB, Johnson MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. CRn. Cancer Res. 5(10), 2672-2673(1999).
8. McLeod HL, Sludden J, Murray GI et al.: Characterization of d1hydropyrimidine dehydrogenase in human colorectal tumours. Br. J Cancer 77 (3), 461-465 (1998).
9. van Kuilenburg AB, Vreken R Abeling NG et al: Genotype and phenotype In patients with dihydropyrimidine dehydrogenase deficiency. Hum. Cenet. 104 (1), 1-9 (1999).
10. Largillier R, Etienne-Grimaldi MC, Formento JL et al.: Pharmacogenetics of capecitabine in advanced breast cancer patients.Clin. Cancer Res. 12(18), 5496-5502 (2006).
11. Saif MW, Diasio R: Is capecitabine safe In patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin. Colorectal Cancer 5 (5), 359-362(2006).
12. Ezzeidin HH, Lee AM, Mattison LK, Diasio RB: Methylation of the DPYD promoter: an alternative mechanism for dilrydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11 (24 Pt 1), 8699-8705 (2005).
13. Lu ZH, Zhang R, Diasio RB: Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. Biochem. Pharmacol. 46(5), 945-952 (1993).
14. Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol. Chem. 267(24), 17102-17109 (1992).
15. van Kuilenburg AB, Dobritzsch D, Meinsma R et al.: Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J. 364(Pt 1), 157-163 (2002).
16. Dobritzsch D, Ricagno S, Schneider G, Schnackerz KD, Lindqvist Y. Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer. J Biol. Chem. 277(15), 13155-13166 (20OZ).
17. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 57(9), 1660-1663 (1997).
18. Wei X, Elizondo G, Sapone A et al.: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51(3), 391-400 (1998).
19. Yokota H, Fernandez-Salguero P, Furuya H et al.: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol. Chm 269 (37), 23192-23196 (1994).
20. Takabayashi A, Iwata S, Kawai Y et al.: Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol. 17 (5), 889-895 (2000).
21. Fujiwara H, Terashima M, Irinoda T et al.: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J. Cancer Res. 93(12), 1342-1350 (2002).
22. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB: Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 278(2), 175-184 (2000).
23. Shestopal SA, Johnson MR, Diasio RB: Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim. Biophys. Acta 1494(1-2), 162-169 (1999).
24. Noguchi T, Tanimoto K, Shimokuni T et al.: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res. 10(20), 7100-7107 (2004).
25. Ukon K, Tanimoto K, Shimokuni T et al.: Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res. 65(3), 1055-1062 (2005).
26. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB: The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim. Biophys. Acta 1759(5), 247-256(2006).
27. Harris BE, Song RL, He YJ, Soong SJ, Diasio RB: Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol. 37(24), 4759-4762 (1988).
28. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between d1hydropyrimicline dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50(1), 197-201 (1990).
29. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB: Relationship between circadian-dependent toxicity of 5-fluoropyrimidine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 53(12), 2816-2822 (1993).
30. Raida M, Kliche KO, Schwabe W et al.: Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J Cancer Res. Clin. Oncol. 128(2), 96-102 (2002).
31. Queener SF, Morris HP, Weber G: Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas. Cancer Res. 31 (7), 1004-1009 (1971).
32. Fujiwaki R, Iida K, Nakayama K et al.: Dihydropyrimidine dehydrogenase in normal and malignant endodometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch. 443(5), 672-677 (2003).
33. Yamada H, Fukushima M, Koizumi K et al.: Regulation of dihydropyrimidine dehydrogenase gene expression In regenerating mouse liver Int. J. Oncol. 22(2), 359-364 (2003).
34. Kashima N, Ueda M, Kanazawa J: Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. Cancer Sci 94(9), 821-825 (2003).
35. Ueda M, Kitaura K, Kusada O et al.: Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. Jpn J. Cancer Res. 91(11), 1185-1191 (2000).
36. Fujii R. Seshimo A, Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J. Clin. Oncol. 8(2), 72-78 (2003).
37. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L: Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol. Int. 18 (4), 709-727 (2001).
38. Collie-Duguid ES, Johnston SJ, Boyce L et al.: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal. cancer. Int. J Cancer 94(2), 297-301 (2001).
39. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K: Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin. Oncol. 18(23). 3946-3951 (2000).
40. Anan K, Mitsuyama S, Tamae K et al.: Increased dihydropyrimidine dehydrogenase activity in breast cancer. J. Surg. Oncol. 82(3), 174-179 (2003).
41. Fukushima M, Morita M, Ikeda K, Nagayama S: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int. J. Mol. Med. 12(6), 839-844 (2003).
42. Nagakawa T, Kayahara M, Ohta T et al.: Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Invest. 18(6), 516-520 (2000).
43. Lu Z, Zhang R, Carpenter JT, Diasio RB: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 4(2), 325-329 (1998).
44. McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J: Autoregulation off 5-fluorouracil metabolism. Eur. J Cancer 34(10), 1623-1627 (1998).
45. Chu S, Ferro TJ: Sp1: regulation of gene expression by phosphoryIation. Gene 348, 1-11 (2005).
46. Fry CJ, Farnham PJ: Context-dependent transcriptional regulation. J Biol. Chem. 274(42), 29583-29586 (1999).
47. Dishart D, Schnur N, Klan N et al.: GC-rich sequences In the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site. Biochim. Biophys. Acta 1738(1-3), 37-47 (2005).
48. Albright SR, Tjian R: TAFs revisited: more data reveal new twists and confirm old ideas. Gene 242(1-2),1-13 (2000).
49. Suske G: The Sp-family of transcription factors. Gene 238(2), 291-300 (1999).
50. Li L, He S, Sun JM, Davie JR: Gene regulation by Spl and Sp3. Biochem. Cell Biol. 82(4), 460-471 (2004).
51. Pang RT, Lee IT, Ng SS, Yung WH, Chow BK: CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol. 18(2), 471-483 (2004).
52. Wong WK, Chen K, Shih JC: Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J Biol. Chem. 278(38), 36227-36235(2003).
53. Chadjichristos C, Ghayor C, Herrouin JF et al.: Down-regulation of human type II collagen. gene expression by transforming growth factor-β 1 (TGF-β 1) in articular chondrocytes involves SP3/SP1 ratio. J Biol. Chem. 277(46), 43903-43917 (2002).
54. Hata Y, Duh E, Zhang K, Robinson GS, Aiello LP: Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol. Chem. 273(30), 19294-19303 (1998).
55. Apt D. Watts RM, Suske G, Bernard HU: High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter. Virology 224(1), 281-291 (1996).
56. Safe S, Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41(16), 2438-2448 (2005).
57. Abdelrahim M, Smith R 3rd, Burghardt R, Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64 (18), 6740-6749 (2004).
58. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
59. Jain PK: Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann. NY Acad. Sci. 983, 71-83 (2003).
60. Momparler RL: Cancer epigenetics. Oncogene 22(42), 6479-6483 (2003).
61. Goffin J, Elsenhauer E: DNA methyltransferase inhibitors-state of the art. Ann. Oncol 13(11), 1699-1716 (2002).
62. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev Cancer 6 (2), 107-116 (2006).
63. Jubb AM, Quirke P, Oates AJ: DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann. NY Acad. Sci. 983, 251-267 (2003).
64. Zhang X, Soong R, Wang K et al.: Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of DPYD promoter; a potentially important epigenetic mechanism regulating DPYD expression. Biochem. Cell Biol. (2007) (In Press).
65. Yu J, McLeod HL, Ezzeldin HH, Diasic, RB: Methylation of the DPYD promoter and dihydropyrimidine, dehydrogenase deficiency. Clin. Cancer Res. 12(12), 3864 (2006).
66. Zhu WG, Srinivasan K, Dal Z et al.: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p2l(Cip1) promoter. Mol. Cell Biol. 23(12), 4056-4065(2003).
67. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8(4), 1063-1067 (1993).
68. Zhang Z, Huettner PC, Nguyen L et al.: Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 25(39), 5436-5445 (2006).
69. Mancini DN, Singh SM, Archer TK, Rodenhiser DI: Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB, SP1 transcription factors. Oncogene 18(28), 4108-4119 (1999).
70. Knoepfler PS, Eisenman RN: Sin meets NuRD and other tails of repression. Cell 99(5), 447-450 (1999).
71. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethytation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1), 103-107 (1999).
72. Shaw RJ, Liloglou T, Rogers SN et al.: Promoter methylation of P16, RARβ, E-cadherin, tyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J Cancer. 94(4), 561-568 (2006).
73. Hasegawa T, Kim HS, Fukushima M, Wataya Y. Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Nucleotides Nucleotides Nucleic Acids 24 (4), 233-242 (2005).
74. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio, RB: DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother. Pharmacol. (2006) (In Press).
75. Sadee W, Dal Z: Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14, R207-R214 (2005).
76. Trakooljul N, Ponsuksili S, Schellander K, Wimmers K: Polymorphisms of the porcine androgen receptor gene affecting its amino acid sequence and'expression level. Biochim. Biophys. Acta 1678(2-3), 94-101 (2004).
77. Schutz S, Schagdarsurengin U, Greiser P et al.: The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis - novel gemomic variants and functional consequences. Hum. Mutat. 20(5), 404 (2002).
78. Curran JE, Jowett JB, Elliott KS et al.: Genetic variation in selenoprotein S influences inflammatory response. Nat. Genet. 37(11), 1234-1241 (2005).
79. LeVan TD, Bloom JW, Bailey TJ et al.: A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances trascriptional activity. J. Immunol. 167(10), 5838-5844 (2001).